These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

16 related articles for article (PubMed ID: 37422012)

  • 1. Oral Orexin Receptor 2 Agonist in Narcolepsy Type 1.
    Dauvilliers Y; Mignot E; Del Río Villegas R; Du Y; Hanson E; Inoue Y; Kadali H; Koundourakis E; Meyer S; Rogers R; Scammell TE; Sheikh SI; Swick T; Szakács Z; von Rosenstiel P; Wu J; Zeitz H; Murthy NV; Plazzi G; von Hehn C
    N Engl J Med; 2023 Jul; 389(4):309-321. PubMed ID: 37494485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A series of 7 cases of patients with narcolepsy with hypocretin deficiency without the HLA DQB1*06:02 allele.
    Miano S; Barateau L; De Pieri M; Riccardi S; Thevenin C; Manconi M; Dauvilliers Y
    J Clin Sleep Med; 2023 Dec; 19(12):2053-2057. PubMed ID: 37539640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orexin Agonist Effective but Not Safe in Narcolepsy Trial.
    Harris E
    JAMA; 2023 Aug; 330(8):686. PubMed ID: 37531144
    [No Abstract]   [Full Text] [Related]  

  • 4. ADRA2B and HTR1A: An Updated Study of the Biogenic Amine Receptors Reveals Novel Conserved Motifs Which Play Key Role in Mental Disorders.
    Papageorgiou L; Christou E; Louka E; Papakonstantinou E; Diakou I; Pierouli K; Dragoumani K; Bacopoulou F; Chrousos GP; Eliopoulos E; Vlachakis D
    Adv Exp Med Biol; 2023; 1423():79-99. PubMed ID: 37525034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of opioids in narcolepsy type 1: A systematic literature review and questionnaire study.
    Gool JK; van Heese EM; Schinkelshoek MS; Remmerswaal A; Lammers GJ; van Dijk KD; Fronczek R
    Sleep Med; 2023 Sep; 109():118-127. PubMed ID: 37437491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orexin mechanisms in the prelimbic cortex modulate the expression of contextual conditioned fear.
    Oliveira GVM; Hernandes PM; Santos FHD; Soares VPMN; Falconi-Sobrinho LL; Coimbra NC; Wotjak CT; Almada RC
    Psychopharmacology (Berl); 2024 Oct; ():. PubMed ID: 39387863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orexin and Sleep Disturbances in Alpha-Synucleinopathies: a Systematic Review.
    Raheel K; See QR; Munday V; Fakhroo B; Ivanenko O; Salvatelli ML; Mutti C; Goadsby PJ; Delogu A; Naismith SL; Holland P; Parrino L; Chaudhuri KR; Rosenzweig I
    Curr Neurol Neurosci Rep; 2024 Sep; 24(9):389-412. PubMed ID: 39031323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rethinking the Role of Orexin in the Regulation of REM Sleep and Appetite.
    Mogavero MP; Godos J; Grosso G; Caraci F; Ferri R
    Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy.
    Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H
    J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy.
    Yamamoto H; Nagumo Y; Ishikawa Y; Irukayama-Tomobe Y; Namekawa Y; Nemoto T; Tanaka H; Takahashi G; Tokuda A; Saitoh T; Nagase H; Funato H; Yanagisawa M
    PLoS One; 2022; 17(7):e0271901. PubMed ID: 35867683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
    Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
    Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.